COMMUNIQUÉS West-GlobeNewswire

-
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
27/11/2017 -
PositiveID Corporation to Present at the LD MICRO “Main Event” Investor Conference on December 6th
27/11/2017 -
iCAD’s PowerLook® Tomo Detection Experiences Growing Adoption
27/11/2017 -
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
27/11/2017 -
Golden Leaf Secures Cultivation License From Health Canada For State-of-the-Art Ontario Grow Facility
27/11/2017 -
Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
27/11/2017 -
Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference
27/11/2017 -
Medovex Corporation Submits IDE with the Food and Drug Administration for its DenerveX System
27/11/2017 -
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
27/11/2017 -
Novo Nordisk A/S - Share repurchase programme
27/11/2017 -
Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
27/11/2017 -
TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
27/11/2017 -
Forward Pharma to Participate in Investor Conferences in December
27/11/2017 -
The Joint Corp. to Present at the 6th Annual Roth Utah Active & Healthy Lifestyle Corp Access Event
27/11/2017 -
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
27/11/2017 -
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
27/11/2017 -
GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017
27/11/2017 -
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome
27/11/2017 -
ContraVir Pharmaceuticals to Make Three Presentations at HEP DART 2017
27/11/2017
Pages